Bevacizumab Plus Irinotecan in Recurrent WHO Grade 3 Malignant Gliomas

PURPOSE: Although patients with newly diagnosed WHO grade 3 malignant glioma have a more favorable prognosis than those with WHO grade 4 malignant glioma, salvage therapies following recurrence offer essentially palliative benefit. We did a phase II trial of bevacizumab, a monoclonal antibody to vas...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Desjardins, Annick, Reardon, David A., Herndon, James E., Marcello, Jennifer, Quinn, Jennifer A., Rich, Jeremy N., Sathornsumetee, Sith, Gururangan, Sridharan, Sampson, John, Bailey, Leighann, Bigner, Darell D., Friedman, Allan H., Friedman, Henry S., Vredenburgh, James J.
Format: Artigo
Idioma:Inglês
Publicat: 2008
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC3671765/
https://ncbi.nlm.nih.gov/pubmed/18981004
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-08-0260
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars